Study: NCT01595516

Intervention type: DRUG
Group type: OTHER
Intervention: Nebivolol
Description: 5 mg tablet to be taken by mouth once per day for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Description: 5 mg tablet to be taken by mouth once per day for 12 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Nebivolol
Description: 5 mg tablet to be taken by mouth once per day for 12 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Nebivolol
Description: 5 mg tablet to be taken by mouth once per day for 12 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Metoprolol
Description: 100 mg tablet to be taken by mouth once per day for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: 100 mg tablet to be taken by mouth once per day for 12 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Metoprolol
Description: 100 mg tablet to be taken by mouth once per day for 12 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Metoprolol
Description: 100 mg tablet to be taken by mouth once per day for 12 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Gelatin capsule to be taken by mouth once per day for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gelatin capsule to be taken by mouth once per day for 12 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Gelatin capsule to be taken by mouth once per day for 12 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Bradykinin
Description: Bradykinin is infused into the brachial artery at doses of 12.5, 25.0 and 50.0 ng/100 mL of forearm tissue /min. BDK stimulates the endothelial cells to release tissue type plasminogen activator (t-PA). Blood flow in mL/100 mL tissue/min is also measured to BDK.

Intervention type: OTHER
Group type: OTHER
Intervention: Bradykinin
Description: Bradykinin is infused into the brachial artery at doses of 12.5, 25.0 and 50.0 ng/100 mL of forearm tissue /min. BDK stimulates the endothelial cells to release tissue type plasminogen activator (t-PA). Blood flow in mL/100 mL tissue/min is also measured to BDK.

Intervention type: OTHER
Group type: OTHER
Intervention: Bradykinin
Description: Bradykinin is infused into the brachial artery at doses of 12.5, 25.0 and 50.0 ng/100 mL of forearm tissue /min. BDK stimulates the endothelial cells to release tissue type plasminogen activator (t-PA). Blood flow in mL/100 mL tissue/min is also measured to BDK.

Intervention type: OTHER
Group type: OTHER
Intervention: Saline
Description: Baseline or resting forearm blood flow is measured in response to saline for 5 minutes before each drug infusion. t-PA release in response to the saline is also measured.

Intervention type: OTHER
Group type: OTHER
Intervention: Saline
Description: Baseline or resting forearm blood flow is measured in response to saline for 5 minutes before each drug infusion. t-PA release in response to the saline is also measured.

Intervention type: OTHER
Group type: OTHER
Intervention: Vitamin C
Description: The acute effects of into-arterial vitamin C on the ability of the endothelium to release t-PA was determined before and after the nebivolol and metoprolol intervention. After allowing sufficient time (\~20 minutes) for FBF and plasma t-PA concentrations to return to baseline following the initial infusion of BDK, vitamin C (24 mg/min) was infused at a constant rate while the BDK dose-response curves were repeated. t-PA and FBF were measured.

Intervention type: OTHER
Group type: OTHER
Intervention: Vitamin C
Description: The acute effects of into-arterial vitamin C on the ability of the endothelium to release t-PA was determined before and after the nebivolol and metoprolol intervention. After allowing sufficient time (\~20 minutes) for FBF and plasma t-PA concentrations to return to baseline following the initial infusion of BDK, vitamin C (24 mg/min) was infused at a constant rate while the BDK dose-response curves were repeated. t-PA and FBF were measured.